Bemis Co Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bemis Co Inc (BMS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bemis Co Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4,064M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (-1.4% annualized vs trailing 12 months).
- Peer revenue share: Bemis Co Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BMS Sales vs. its Competitors, Q1 2019
Bemis Co Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Paper & Paper Products industry grew revenue 2.3% year over year, combined, vs -2.5% for Bemis Co Inc. Bemis Co Inc's share of combined industry revenue moved from 2.98% to 2.84%, a loss of 0.14 percentage points.
Bemis Co Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bemis Co Inc | Yes | No | No | No |
| High-Confidence Competitors (21) | ||||
| Similar Growth & Profitability (8) | 75.00 % (6 of 8) | 75.00 % (6 of 8) | 62.50 % (5 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BMS Stock Performance relative to its Competitors
BMS Stock Performance relative to High-Confidence Competitors
BMS Stock Performance relative to Similar Growth & Profitability Competitors
Bemis Co Inc's Competitors Named by the Company
Competitive relationships identified from Bemis Co Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Cardiff Oncology Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Puretech Health Plc | Company report | 85% |
| Cytosorbents Corporation | Company report | 85% |
| Kura Oncology Inc | Company report | 85% |
| Liminatus Pharma Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Ayala Pharmaceuticals Inc | Company report | 85% |
| Edgewise Therapeutics inc | Company report | 85% |
| Agenus Inc | Company report | 85% |
| Autolus Therapeutics Plc | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Altamira Therapeutics Ltd | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Agape Atp Corporation | Company report | 85% |
| Schrodinger Inc | Company report | 85% |
| Exscientia Plc | Company report | 85% |
| Seagen Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Urogen Pharma Ltd | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Replimune Group Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Bemis Co Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Bemis Co Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.